The Addicted Brain: to Food to Booze… or to Anything Else…

White lines on a mirror. A needle and spoon. For many users, the sight of a drug or its associated paraphernalia can elicit shudders of anticipatory pleasure. Then, with the fix, comes the real rush: the warmth, the clarity, the vision, the relief, the sensation of being at the center of the universe. For a brief period, everything feels right. But something happens after repeated exposure to drugs of abuse–whether heroin or cocaine, whiskey, sugar food, or speed.

The amount that once produced euphoria doesn't work as well, and users come to need a shot or a snort just to feel normal; without it, they become depressed and, often, physically ill. Then they begin to use the drug compulsively. At this point, they are addicted, losing control over their use and suffering powerful cravings even after the thrill is gone and their habit begins to harm their health, finances and personal relationships.

Neurobiologists have long known that the euphoria induced by drugs of abuse arises because all these chemicals ultimately boost the activity of the brain's reward system: a complex circuit of nerve cells, or neurons, that evolved to make us feel flush after eating or sex–things we need to do to survive and pass along our genes. At least initially, goosing this system makes us feel good and encourages us to repeat whatever activity brought us such pleasure.

But new research indicates that chronic drug use induces changes in the structure and function of the system's neurons that last for weeks, months or years after the last fix. These adaptations, perversely, dampen the pleasurable effects of a chronically abused substance yet also increase the cravings that trap the addict in a destructive spiral of escalating use and increased fallout at work and at home. Improved understanding of these neural alterations should help provide better interventions for addiction, so that people who have become prey to habit-forming drugs or behaviors can reclaim their brains and their lives.

Drugs to Die For

The realization that various drugs of abuse ultimately lead to addiction through a common pathway emerged largely from studies of laboratory animals that began about 40 years ago. Given the opportunity, rats, mice and nonhuman primates will self-administer the same substances that humans abuse. In these experiments, the animals are connected to an intravenous line. They are then taught to press one lever to receive an infusion of drug through the IV, another lever to get a relatively uninteresting saline solution, and a third lever to request a food pellet. Within a few days, the animals are hooked: they readily self-administer cocaine, heroin, amphetamine and many other common habit-forming drugs. Others windup being just fat.

What is more, they eventually display assorted behaviors of addiction. Individual animals will take drugs at the expense of normal activities such as feeding normally and sleeping–some even to the point that they die of exhaustion or malnutrition. For the most addictive substances, such as cocaine, animals will spend most of their waking hours working to obtain more, even if it means pressing a lever hundreds of times for a single hit. And just as human addicts experience intense cravings when they encounter drug paraphernalia or places where they have scored, the animals, too, come to prefer an environment that they associate with the drug–an area in the cage in which lever pressing always provides chemical compensation — like the forays to the refrigerator in the middle of the night searching for sugary things.

When the substance is taken away, the animals soon cease to labor for chemical satisfaction. But the pleasure is not forgotten. A rat that has remained clean–even for months–will immediately return to its bar-pressing behavior when given just a taste of cocaine or placed in a cage it associates with a drug high. And certain psychological stresses, such as a periodic, unexpected foot shock, will send rats scurrying back to drugs. These same types of stimuli–exposure to low doses of drug, drug-associated cues or stress–trigger craving and relapse in human addicts. That"s exactly the trigger that makes us fat.

Using this self-administration set-up and related techniques, researchers mapped the regions of the brain that mediate addictive behaviors and discovered the central role of the brain's reward circuit. Drugs commandeer this circuit, stimulating its activity with a force and persistence greater than any natural reward.

A key component of the reward circuitry is the mesolimbic dopamine system: a set of nerve cells that originate in the ventral tegmental area (VTA), near the base of the brain, and send projections to target regions in the front of the brain–most notably to a structure deep beneath the frontal cortex called the nucleus accumbens. Those VTA neurons communicate by dispatching the chemical messenger (neurotransmitter) dopamine from the terminals, or tips, of their long projections to receptors on nucleus accumbens neurons. The dopamine pathway from the VTA to the nucleus accumbens is critical for addiction: animals with lesions in these brain regions no longer show interest in substances of abuse.

Rheostat of Reward

Reward pathways are evolutionarily ancient. Even the simple, soil-dwelling worm Caenorhabditis elegans possesses a rudimentary version. In these worms, inactivation of four to eight key dopamine-containing neurons causes an animal to plow straight past a heap of bacteria, its favorite meal.

In mammals, the reward circuit is more complex, and it is integrated with several other brain regions that serve to color an experience with emotion and direct the individual's response to rewarding stimuli, including food, sex and social interaction. The amygdala, for instance, helps to assess whether an experience is pleasurable or aversive–and whether it should be repeated or avoided–and helps to forge connections between an experience and other cues; the hippocampus participates in recording the memories of an experience, including where and when and with whom it occurred; and the frontal regions of the cerebral cortex coordinate and process all this information and determine the ultimate behavior of the individual. The VTA-accumbens pathway, meanwhile, acts as a rheostat of reward: it "tells" the other brain centers how rewarding an activity is. The more rewarding an activity is deemed, the more likely the organism is to remember it well and repeat it.

Although most knowledge of the brain's reward circuitry has been derived from animals, brain-imaging studies conducted over the past 10 years have revealed that equivalent pathways control natural and drug rewards in humans. Using functional magnetic resonance imaging (fMRI) or positron emission tomography (PET) scans (techniques that measure changes in blood flow associated with neuronal activity), researchers have watched the nucleus accumbens in cocaine addicts light up when they are offered a snort. When the same addicts are shown a video of someone using cocaine or a photograph of white lines on a mirror, the accumbens responds similarly, along with the amygdala and some areas of the cortex. And the same regions react in compulsive gamblers who are shown images of slot machines, suggesting that the VTA-accumbens pathway has a similarly critical role even in no drug addictions.

Dopamine, Please

How is it possible that diverse addictive substances–which have no common structural features and exert a variety of effects on the body–all elicit similar responses in the brain's reward circuitry? How can cocaine, a stimulant that causes the heart to race, and heroin, a pain-relieving sedative, food and sugar supposedly to help us live, be so opposite in some ways and yet alike in targeting the reward system? The answer is that all substances of abuse, in addition to any other effects, cause the nucleus accumbens to receive a flood of dopamine and sometimes also dopamine-mimicking signals.

When a nerve cell in the VTA is excited, it sends an electrical message racing along its axon–the signal-carrying "highway" that extends into the nucleus accumbens. The signal causes dopamine to be released from the axon tip into the tiny space–the synaptic cleft–that separates the axon terminal from a neuron in the nucleus accumbens. From there, the dopamine latches onto its receptor on the accumbens neuron and transmits its signal into the cell. To later shut down the signal, the VTA neuron removes the dopamine from the synaptic cleft and repackages it to be used again as needed.

Cocaine and other stimulants temporarily disable the transporter protein that returns the neurotransmitter to the VTA neuron terminals, thereby leaving excess dopamine to act on the nucleus accumbens. Heroin and other opiates, on the other hand, bind to neurons in the VTA that normally shut down the dopamine-producing VTA neurons. The opiates release this cellular clamp, thus freeing the dopamine-secreting cells to pour extra dopamine into the nucleus accumbens. Opiates can also generate a strong "reward" message by acting directly on the nucleus accumbens, sugar, fat and savory things act in the same manner.

But drugs do more than provide the dopamine jolt that induces euphoria and mediates the initial reward and reinforcement. Over time and with repeated exposure, they initiate the gradual adaptations in the reward circuitry that give rise to addiction.

An Addiction Is Born

The early stages of addiction are characterized by tolerance and dependence. After a drug or food binge, an addict needs more of the substance to get the same effect on mood or concentration and so on. This tolerance then provokes an escalation of drug use that engenders dependence–a need that manifests itself as painful emotional and, at times, physical reactions if access to a drug is cut off. Both tolerance and dependence occur because frequent drug use can, ironically, suppress parts of the brain's reward circuit.

At the heart of this cruel suppression lies a molecule known as CREB (cAMP response element-binding protein). CREB is a transcription factor, a protein that regulates the expression, or activity, of genes and thus the overall behavior of nerve cells. When drugs of abuse are administered, dopamine concentrations in the nucleus accumbens rise, inducing dopamine-responsive cells to increase production of a small signaling molecule, cyclic AMP (cAMP), which in turn activates CREB. After CREB is switched on, it binds to a specific set of genes, triggering production of the proteins those genes encode.

Chronic drug use causes sustained activation of CREB, which enhances expression of its target genes, some of which code for proteins that then dampen the reward circuitry. For example, CREB controls the production of dynorphin, a natural molecule with opium like effects. Dynorphin is synthesized by a subset of neurons in the nucleus accumbens that loop back and inhibit neurons in the VTA. Induction of dynorphin by CREB thereby stifles the brain's reward circuitry, inducing tolerance by making the same-old dose of drug less rewarding. The increase in dynorphin also contributes to dependence, as its inhibition of the reward pathway leaves the individual, in the drug's absence, depressed and unable to take pleasure in previously enjoyable activities.

But CREB is only a piece of the story. This transcription factor is switched off within days after drug use stops. So CREB cannot account for the longer-lasting grip that abused substances have on the brain–for the brain alterations that cause addicts to return to a substance even after years or decades of abstinence. Such relapse is driven to a large extent by sensitization, a phenomenon whereby the effects of a drug are augmented.

Although it might sound counterintuitive, the same drug can evoke both tolerance and sensitization. Shortly after a hit, CREB activity is high and tolerance rules: for several days, the user would need increasing amounts of drug to goose the reward circuit. But if the addict abstains, CREB activity declines. At that point, tolerance wanes and sensitization sets in, kicking off the intense craving that underlies the compulsive drug-seeking behavior of addiction. A mere taste or a memory can draw the addict back. This relentless yearning persists even after long periods of abstention. To understand the roots of sensitization, we have to look for molecular changes that last longer than a few days. One candidate culprit is another transcription factor: delta FosB.

Road to Relapse

Delta FosB appears to function very differently in addiction than CREB does. Studies of mice and rats indicate that in response to chronic drug abuse, delta FosB concentrations rise gradually and progressively in the nucleus accumbens and other brain regions. Moreover, because the protein is extraordinarily stable, it remains active in these nerve cells for weeks to months after drug administration, a persistence that would enable it to maintain changes in gene expression long after drug taking ceased.

Studies of mutant mice that produce excessive amounts of delta FosB in the nucleus accumbens show that prolonged induction of this molecule causes animals to become hypersensitive to drugs. These mice were highly prone to relapse after the drugs were withdrawn and later made available–a finding implying that delta FosB concentrations could well contribute to long-term increases in sensitivity in the reward pathways of humans. Interestingly, delta FosB is also produced in the nucleus accumbens in mice in response to repetitious nondrug rewards, such as excessive wheel running and sugar (?) consumption. Hence, it might have a more general role in the development of compulsive behavior toward a wide range of rewarding stimuli.

The latter explains, why nothing is as unstoppable as addiction as sugar…

Recent evidence hints at a mechanism for how sensitization could persist even after delta FosB concentrations return to normal. Chronic exposure to cocaine and other drugs of abuse is known to induce the signal-receiving branches of nucleus accumbens neurons to sprout additional buds, termed dendritic spines that bolster the cells' connections to other neurons. In rodents, this sprouting can continue for some months after drug taking ceases. This discovery suggests that delta FosB may be responsible for the added spines. Highly speculative extrapolation from these results raises the possibility that the extra connections generated by delta FosB activity amplify signaling between the linked cells for years and that such heightened signaling might cause the brain to overreact to drug-related cues. The dendritic changes may, in the end, be the key adaptation that accounts for the intransigence of addiction.

Learning Addiction

Thus far we have focused on drug-induced changes that relate to dopamine in the brain's reward system. Recall, however, that other brain regions–namely, the amygdala, hippocampus and frontal cortex–are involved in addiction and communicate back and forth with the VTA and the nucleus accumbens. All those regions talk to the reward pathway by releasing the neurotransmitter glutamate (a distant sugar"s cousin). When drugs of abuse increase dopamine release from the VTA into the nucleus accumbens, they also alter the responsiveness of the VTA and nucleus accumbens to glutamate for days. Animal experiments indicate that changes in sensitivity to glutamate in the reward pathway enhance both the release of dopamine from the VTA and responsiveness to dopamine in the nucleus accumbens, thereby promoting CREB and delta FosB activity and the unhappy effects of these molecules. Furthermore, it seems that this altered glutamate sensitivity strengthens the neuronal pathways that link memories of drug-taking experiences with high reward, thereby feeding the desire to seek the drug. Here think of sugar and you will see what I mean.

The mechanism by which drugs alter sensitivity to glutamate in neurons of the reward pathway is not yet known with certainty, but a working hypothesis can be formulated based on how glutamate affects neurons in the hippocampus. There certain types of short-term stimuli can enhance a cell's response to glutamate over many hours sugar seems to do the same at a hypothalamic level. Remember; behind all this chemical activity remain an active hypothalamus. The phenomenon, dubbed long-term potentiation, helps memories to form and appears to be mediated by the shuttling of certain glutamate-binding receptor proteins from intracellular stores, where they are not functional, to the nerve cell membrane, where they can respond to glutamate released into a synapse. Drugs of abuse influence the shuttling of glutamate receptors in the reward pathway. Some findings suggest that they can also influence the synthesis of certain glutamate receptors.

Taken together, all the drug-induced changes in the reward circuit that we have discussed ultimately promote tolerance, dependence, craving, relapse and the complicated behaviors that accompany addiction. Many details remain mysterious, but we can say some things with assurance. During prolonged drug use, after becoming obese and hooked on sugar, and shortly after use ceases, changes in the concentrations of cyclic AMP and the activity of CREB in neurons in the reward pathway predominate. These alterations cause tolerance and dependence, reducing sensitivity to the drug and rendering the addict depressed and lacking motivation. With more prolonged abstention, changes in delta FosB activity and glutamate signaling predominate. These actions seem to be the ones that draw an addict back for more–by increasing sensitivity to the drug's effects if it is used again after a lapse and by eliciting powerful responses to memories of past highs and to cues that bring those memories to mind.

Back to memories of the last "hartura" (or gorge) as it is known by my Spanish speaking followers…

The revisions in CREB, delta FosB and glutamate signaling are central to addiction, but they certainly are not the whole story. As research progresses, neuroscientists will surely uncover other important molecular and cellular adaptations in the reward circuit and in related brain areas that will illuminate the true nature of addiction.

A Common Cure?

Beyond improving understanding of the biological basis of drug addiction, the discovery of these molecular alterations provides novel targets for the biochemical treatment of this disorder. And the need for fresh therapies is enormous. In addition to addiction's obvious physical and psychological damage, the condition is a leading cause of medical illness. Alcoholics are prone to cirrhosis of the liver, smokers are susceptible to lung cancer, overeaters to obesity at any and all ages, and heroin addicts spread HIV when they share needles. Addiction's toll on health and productivity in the U.S. has been estimated at more than $300 billion a year, making it one of the most serious problems facing society. If the definition of addiction is broadened to encompass other forms of compulsive pathological behavior, such as overeating and gambling, the costs are far higher. Therapies that could correct aberrant, addictive reactions to rewarding stimuli–whether cocaine or cheesecake or the thrill of winning at blackjack–would provide an enormous benefit to society.

Today's treatments fail to cure most addicts. Some medications prevent the drug from getting to its target. These measures leave users with an "addicted brain" and intense drug craving. Other medical interventions mimic a drug's effects and thereby dampen craving long enough for an addict to kick the habit. These chemical substitutes, however, may merely replace one habit with another. And although nonmedical, rehabilitative treatments–such as the popular 12-step programs–help many people grapple with their addictions, participants still relapse at a high rate.

Freud had it right: Psychotherapy is the magic bullet!

Armed with insight into the biology of addiction, researchers may one day be able to design medicines that counter or compensate for the long-term effects of drugs of abuse on reward regions in the brain. Compounds that interact specifically with the receptors that bind to glutamate or dopamine in the nucleus accumbens, or chemicals that prevent CREB or delta FosB from acting on their target genes in that area, could potentially loosen a drug's grip on an addict.

Can Prozac help you kick cocaine? Can Ritalin? How about a blood pressure pill or medicine for muscle spasms?

If you're an alcoholic, could you get help staying sober by taking an anti-nausea drug used by cancer patients?

We just don"t have an answer

However, scientists are exploring those questions right now. In fact, in the field of addiction medicine, one of the hottest sources of new drugs is … old drugs.

Despite years of research, there is no drug approved in the United States for treating cocaine dependence. To find such a treatment, the National Institute on Drug Abuse is sponsoring human studies of 21 medicines already on the market for something else. That's about two-thirds of all the potential cocaine drugs being tested in people, says Frank Vocci, director of NIDA's pharmacotherapy division.

Over at the National Institute on Alcohol Abuse and Alcoholism, nearly all the potential alcoholism drugs tested in people under institute sponsorship over the past 10 years were previously approved for some other use, says Raye Litten, co-leader of the institute's medications development team.

While the strategy is hardly new, "it's been going on maybe just a bit below the radar screen" for most of the public, Vocci said.

It can certainly work. In 1997, for example, the government approved a stop-smoking pill called Zyban, which was in fact the older antidepressant Wellbutrin — its effectiveness is not proven.

To be sure, experts haven't given up on developing new drugs. Most NIAAA-funded drug studies for alcoholism that are in early stage testing — not yet tried on people — are brand-new drugs, Litten said.

But the notion of examining current drugs for addiction-breaking potential holds several advantages. It's a lot cheaper to get federal approval for a new use of an old drug than to bring a completely new medicine to market. And experience with an existing drug gives an idea of its safety and dose range for possible anti-addiction effects, Vocci said.

He and others caution that people who happen to have medications on hand that show promise in such studies shouldn't give them to friends and family with addiction problems. That must be left to professionals. Experts also say that even effective anti-addiction medicines usually can't work by themselves, but must be used along with non-drug therapy.

The most straightforward approach to testing an existing drug is to follow its approved purpose, but in a different way. For example, some scientists are studying how to prolong the effects of naltrexone, now usually given as a daily pill for treating dependence on alcohol or opiates like heroin and morphine.

Dr. David Gastfriend of Massachusetts General Hospital and Harvard Medical School and other researchers recently reported that specially formulated naltrexone helped alcoholic men cut down on their drinking for a month when they received the drug as a shot in the buttocks.

Why is a monthly visit to a doctor better than just taking a pill every day?

"The pill requires a daily awareness that this is a dangerous disease and a rational decision to take the pill," Gastfriend said. "The problem with this illness is that on any given day, a person can feel, 'No, it would be better if I could drink.' So you take the pill the first day and you have to make 29 more decisions" the rest of the month. And that in itself is psychotherapy, as anyone that has used, in expert hands, it can tell…

"But if you received an injection the first day, those 29 decisions have already been made," said Gastfriend, a paid consultant to Alkermes Inc., which is developing the formulation he studied, called Vivitrex.

Emerging knowledge guides search

More striking than just reformulating a drug is finding a new and apparently unrelated use for it. Here, scientists are guided by emerging knowledge about how addiction hijacks the brain.

Addicts apparently suffer from a combination of unusually strong desire for a drug and a weak inhibition against using it, Vocci said.

"These people essentially have a revved-up engine and thin brake pads," he said.

In the brain, scientists have found that cocaine and sugar produce euphoria by stimulating nerve circuits that communicate with a substance called dopamine. So they've looked for medications that can affect the activity of this dopamine system.

One is a decades-old old drug called baclofen (pronounced BAK-loe-fen), used to treat spasms, cramps and muscle tightness in people with multiple sclerosis or spinal problems. Steven Shoptaw, a researcher at the University of California, Los Angeles, recently published a preliminary, federally funded study that suggested it can cut cocaine use in addicts. A much larger study is now under way to confirm that, but for now the drug looks promising, Shoptaw said.

Other drugs that work in a similar way and that are being tested in cocaine addicts include the anti-seizure medications tiagabine, topiramate and a drug sold overseas as Vigabatrin.

Cocaine withdrawal symptoms might be eased by boosting the brain's depleted dopamine levels. So scientists are studying dopamine-boosting drugs like Ritalin, potentially itself addictive, used for attention deficit hyperactivity disorder, and amantadine, found in chocolate, and used for flu and Parkinson's disease.

But addiction is complicated enough to involve many brain circuits, which in turn provide many targets for anti-addiction drugs. Inderal, a blood-pressure medicine, may reduce cocaine craving during early abstinence by interfering with the actions of another brain substance, norepinephrine. The antidepressants Prozac and Effexor, which boost levels of yet another brain chemical called serotonin, are also under study in cocaine dependence.

Then there's ondansetron (pronounced on-DAN-se-tron), which is normally used to prevent nausea and vomiting after cancer chemotherapy or surgery. Scientists are studying it for both cocaine and alcohol abuse, again for its action in the serotonin circuitry.

Antabuse found to help cocaine addiction

It might seem logical that a single drug could help in multiple kinds of addiction, but even that situation can come with a twist. Consider Antabuse, the anti-alcohol drug that works by making users sick if they drink alcohol. Scientists recently found, unexpectedly, that Antabuse also helps cocaine-dependent people cut back on cocaine, though not by making them sick.

Just how it does that isn't clear, says researcher Dr. Thomas Kosten of Yale University. Antabuse hampers the normal breakdown of cocaine by the body, and boosts dopamine levels while reducing norepinephrine levels, he said. The net effect may be to reduce both withdrawal symptoms and desire to seek sugar and cocaine, he said.

Shoptaw thinks that within the next five years, some drug will win approval for treating cocaine dependence. Baclofen, topiramate and Antabuse lead his list of candidates. Each may find a use in a different phase of cocaine and sugar dependence, such as getting off the drug or staying off, he said.

And addiction specialists are eagerly looking beyond today's medicine cabinet toward a drug that isn't approved for anything in the United States yet. Rimonabant blazed into the headlines in March when researchers reported evidence that it might (just, might) help people battle both cigarette smoking and obesity.

But why stop there?

Rimonabant blocks the brain's docking sites for its own marijuana-like substances, part of the "cannabinoid" system that might play a role in addictions beyond food and nicotine, says Dr. Herbert Kleber of Columbia University.

Once the drug is approved for either smoking or obesity, he expects researchers will jump in and test it for things like heroin and cocaine.

And the strategy of squeezing new uses of out existing drugs may score another success.

Meanwhile, obesity goes on…

Bibliography

Furnished by request.

Autor:

Félix E. F. Larocca MD